Form 4: Amphastar Pharmaceuticals Director Diane G. Gerst Acquires Significant Equity Stake

Amphastar Pharmaceuticals, Inc. Director Diane G. Gerst has acquired 5,122 restricted stock units and 11,402 stock options, aligning her interests with shareholders.

Summary

• Diane G. Gerst, a Director of Amphastar Pharmaceuticals, Inc. (AMPH), reported the acquisition of equity securities.
• On June 2, 2025, Ms. Gerst acquired 5,122 shares of Common Stock in the form of Restricted Stock Units (RSUs) at a price of $0 per share.
• These RSUs are scheduled to vest on June 2, 2026.
• Additionally, Ms. Gerst acquired 11,402 stock options with an exercise price of $25.38 per share.
• These stock options also vest on June 2, 2026, and have an expiration date of June 3, 2034.
• Following these transactions, Ms. Gerst beneficially owns 23,756 shares of Common Stock and 11,402 stock options.

Sentiment

Score: 7

Explanation: The acquisition of equity by a director, particularly through RSUs and stock options, is generally viewed positively as it aligns the director's interests with shareholder value creation. It indicates a commitment to the company's long-term success. However, it's a compensation event, not a direct market purchase, so the positive sentiment is moderate.

Positives

• The acquisition of restricted stock units and stock options by a director aligns management's interests with those of shareholders, as their compensation is tied to the company's future performance.
• The vesting schedule for both RSUs and stock options on June 2, 2026, indicates a long-term commitment from the director.

Negatives

• The document does not present any negative information regarding the company's operations or financial health.

Risks

• The value of the acquired restricted stock units and stock options is subject to the future performance of Amphastar Pharmaceuticals' stock price.
• There is a risk that the stock price may not appreciate sufficiently for the stock options to be in-the-money or for the RSUs to retain significant value upon vesting.

Future Outlook

The vesting of the acquired restricted stock units and stock options on June 2, 2026, indicates a future alignment of the director's financial interests with the long-term performance of Amphastar Pharmaceuticals, Inc.

Industry Context

This Form 4 filing details an individual insider transaction, which is a routine disclosure for publicly traded companies. It does not provide broader industry trends or competitive analysis, but rather reflects a standard component of executive and director compensation packages in the pharmaceutical industry, aiming to incentivize long-term performance.

Comparison to Industry Standards

• The compensation structure involving restricted stock units and stock options for directors is a common practice across various industries, including pharmaceuticals.
• While specific comparable companies or projects are not mentioned in this filing, such equity grants are standard mechanisms used by companies like Pfizer, Johnson & Johnson, or Merck to align director incentives with shareholder value creation.
• The specific number of units and options granted would typically be benchmarked against peer group compensation data, though such benchmarking details are not provided in this Form 4.

Related Party Transactions

• The acquisition of 5,122 restricted stock units and 11,402 stock options by Diane G. Gerst, a director of Amphastar Pharmaceuticals, Inc., represents a compensation-related transaction between the company and a related party.

Stakeholder Impact

• Shareholders: The equity grants to a director align their financial interests with the long-term performance of the company, potentially benefiting shareholders if the stock price appreciates.
• Employees: No direct impact on general employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Next Steps

• The acquired restricted stock units and stock options are scheduled to vest on June 2, 2026.
• The stock options have an expiration date of June 3, 2034, by which time they must be exercised if in-the-money.

Key Dates

Keywords

Amphastar Pharmaceuticals, AMPH, SEC Form 4, Insider Trading, Restricted Stock Units, Stock Options, Director Compensation, Equity Acquisition, Beneficial Ownership